Genomics

Dataset Information

0

Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes


ABSTRACT: Human clinical trials in type 1 diabetes (T1D) patients are underway using mesenchymal stem cells (MSC) without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in non-obese diabetic (NOD) mice. In comparison to NOD-, BALB/c-MSC express higher levels of the negative costimulatory molecule PD-L1 and promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e. NOR or BALB/c), but not from NOD mice, conferred disease protection when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NOD-MSC. Administration of BALB/c-MSC resulted in reversal of hyperglycemia in 90% of NOD mice (p=0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit, and in fact soft tissue and visceral tumors were uniquely observed in this setting (i.e. no tumors were present with BALB/c- or NOR-MSC transfer). These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and potentially, other autoimmune disorders.

ORGANISM(S): Mus musculus

PROVIDER: GSE15516 | GEO | 2009/04/02

SECONDARY ACCESSION(S): PRJNA115683

REPOSITORIES: GEO

Similar Datasets

2010-06-20 | E-GEOD-15516 | biostudies-arrayexpress
2011-10-07 | BIOMD0000000381 | BioModels
2012-07-31 | E-MEXP-3572 | biostudies-arrayexpress
2012-07-31 | E-MEXP-3573 | biostudies-arrayexpress
2023-03-11 | PXD035504 | Pride
2021-08-13 | GSE155593 | GEO
2016-10-07 | GSE87677 | GEO
2018-02-28 | GSE104644 | GEO
2020-05-31 | GSE146452 | GEO
2019-03-29 | GSE128315 | GEO